| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.4 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.15 | 0.4 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |